- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00001676
Cyclophosphamide and Fludarabine to Treat Lupus Nephritis
Combination of Cyclophosphamide and Fludarabine for Lupus Nephritis: Tolerance, Toxicity, Efficacy and Effects on B and T Lymphocyte Regeneration
This study will test the safety and effectiveness of combination therapy with cyclophosphamide (Cytoxan) and fludarabine in treating lupus nephritis (kidney inflammation). This condition, common in patients with systemic lupus erythematosus, is caused by abnormal action of immune cells called lymphocytes against the kidneys. Left untreated, severe cases can result in loss of kidney function. The current treatment of choice-intermittent high doses (pulses) of cyclophosphamide-does not work in all patients and causes infertility in many women. The rate of infertility in men is not known. This study will examine whether fludarabine can safely be given with significantly lower doses of cyclophosphamide, and if this combination controls kidney inflammation.
Patients 18 years of age and older with severe lupus nephritis (called proliferative lupus nephritis) may be eligible for this study. Candidates will have a history and physical examination; blood and urine tests; chest X-ray; electrocardiogram; cancer screening that may include a Pap smear, mammogram, rectal examination, PSA testing, and sigmoidoscopy.
Participants will be divided into one of the following treatment groups:
Group 1-Patients undergo three treatment cycles of cyclophosphamide, taken by mouth, and fludarabine, injected subcutaneously (under the skin). Patients receive both drugs on day 1 of the cycle, and fludarabine alone on days 2 and 3. This regimen is repeated once every 5 weeks for three cycles.
Group 2-Same as for Group 1, except fludarabine injections are given intravenously (through a vein) for the second treatment cycle. Patients in this group have frequent blood sampling during the first and second treatment cycles to monitor blood levels of the drug. Samples are collected before the first injection is given and at 0.5, 1, 1.5, 2, 4, 8, 24 and 48 hours after the third injection. A total 12 tablespoons of blood is drawn over a 2-month period.
All patients will have blood drawn once or twice a week during the first two cycles and then less frequently to monitor blood counts. Some patients will have the following additional procedures to test the effects of treatment on lymphocytes:
- Blood sample collection
- Bone marrow aspiration-The skin over the hip bone is cleaned and a local anesthetic is injected into the outer covering of the bone. Bone marrow is suctioned through the needle into an attached syringe. The procedure is done before treatment begins, at the end of treatment, and 6 months after treatment.
- Tonsillar biopsy-The tonsils are numbed with a local anesthetic and 1 to 4 pieces of tissue are removed using special forceps. The procedure is done before treatment begins, at the end of treatment, and 6 months after treatment.
- Magnetic resonance imaging (MRI) of the abdomen-The patients lies on a table in a narrow cylinder (the MRI scanner) containing a strong magnetic field, which is used to create images of parts of the body in small section views.
Patients will be followed for at least 24 months to monitor late side effects and the response to treatment.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Maryland
-
Bethesda, Maryland, Forente stater, 20892
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Patients must be 18 years of age or older and able to provide informed consent.
Patients must have at least 4 criteria for SLE as defined by the American Rheumatism Association (ARA).
Active glomerulonephritis with:
Renal biopsy within 1 year with class III or class IV active lupus nephritis, AND;
Abnormal urine analysis:
Greater than 10 RBC/hpf and cellular (RBC, WBC or mixed) casts, OR;
Greater than 10 RBC/hpf and proteinuria greater than 2 g/day, OR;
Proteinuria greater than 3.5 g/day.
No patients with severe proliferative lupus nephritis: a. very active renal histology with crescents or necrosis in more than 25% of glomeruli; or b. rapidly progressive glomerulonephritis (doubling of serum creatinine in less than or equal to 3 months); or c. severe impairment of renal function Cr greater than 2.5 mg/dL or GFR less than 50 mL/min measured by inulin clearance.
Patient has not had previous immunosuppressive therapy:
Patients must not be receiving azathioprine, cyclosporine, methotrexate. Patients receiving these drugs will be eligible only if these drugs are discontinued and after a waiting period of greater than or equal to 4 weeks;
Patients must not be receiving cyclophosphamide:
Greater than 3 pulses (maximum 1 g/m(2)/pulse) within the last 12 months or since last renal biopsy showing active disease; OR
greater than 6 pulses ever.
Patients must not have had pulse therapy with glucocorticoids or any experimental therapy during the 4 weeks before study entry.
Patients who need at study entry oral corticosteroids in dosages greater than 0.5 mg/kg/day of predisone to control extrarenal disease are not eligible.
Patients with active or chronic infection are not eligible.
Patients who are pregnant, breast-feeding or using inadequate birth control are not eligible.
Patients who have poorly controlled diabetes mellitus or with evidence of end-organ damage are not eligible.
No history of cerebrovascular accident, seizures within the last 5 years or chronic neurologic disease.
No history of malignancy other than squamous cell and/or basal carcinoma of the skin.
No confounding medical illness that in the judgment of investigators would pose added risk for study participants such as:
Unstable coronary artery disease, cardiomyopathy or dysrhythmia requiring therapy;
Pulmonary disease (PFTs less 70% of predicted value or DLCO less than 60%), or;
Hematologic disease (Hb less than 8 mg/dL, platelets less than 100,000 micro liters or WBC less than 2,500/micro liters.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
Samarbeidspartnere og etterforskere
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992 Sep 26;340(8822):741-5. doi: 10.1016/0140-6736(92)92292-n.
- Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996 Oct 1;125(7):549-57. doi: 10.7326/0003-4819-125-7-199610010-00003.
- Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993 Sep 1;119(5):366-9. doi: 10.7326/0003-4819-119-5-199309010-00003.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 980055
- 98-AR-0055
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Systemisk lupus erythematosus
-
BiogenRekrutteringSubakutt kutan lupus erythematosus | Kronisk kutan lupus erythematosusForente stater, Italia, Korea, Republikken, Taiwan, Argentina, Chile, Spania, Canada, Serbia, Frankrike, Tyskland, Brasil, Storbritannia, Puerto Rico, Bulgaria, Portugal, Sveits, Filippinene, Japan, Saudi-Arabia, Sverige, Mexico, Polen, Ungar... og mer
-
BiogenPåmelding etter invitasjonSubakutt kutan lupus erythematosus | Kronisk kutan lupus erythematosusSpania, Forente stater, Sverige
-
Florida Academic Dermatology CentersUkjentDiscoid Lupus Erythematosus (DLE)Forente stater
-
Bristol-Myers SquibbRekrutteringLupus erythematosus, Discoid | Lupus erythematosus, subakutt kutanForente stater, Mexico, Den russiske føderasjonen, Australia, Argentina, Polen, Frankrike, Tyskland, Taiwan
-
SanofiFullførtKutan lupus erythematosus-systemisk lupus erythematosusJapan
-
AmgenFullført
-
LEO PharmaAvsluttetDiscoid lupus erythematosusForente stater, Frankrike, Tyskland, Danmark
-
University of RochesterIncyte CorporationFullførtDiscoid lupus erythematosusForente stater
-
Massachusetts General HospitalNovartisTilbaketrukketDiscoid lupus erythematosusForente stater
-
University of PennsylvaniaRekrutteringKutan lupus erythematosus (CLE)Forente stater
Kliniske studier på SQ Fludarabine
-
Eli Lilly and CompanyFullførtLeddgiktBulgaria, Polen, Moldova, Republikken, Romania
-
Beijing Tongren HospitalFullført
-
Novartis PharmaceuticalsFullførtSesongbetinget allergisk rhinittStorbritannia
-
Radboud University Medical CenterFullført
-
ALK-Abelló A/SInflamax Research IncorporatedFullførtAllergisk rhinokonjunktivittCanada
-
University of PittsburghCSL BehringFullførtInfeksjoner etter lungetransplantasjonForente stater
-
Guy's and St Thomas' NHS Foundation TrustUkjentBruk av subkutane ICD-er etter infeksjon
-
Bispebjerg HospitalLund University; University of Copenhagen; ALK-Abelló A/SFullførtAllergisk astma på grunn av Dermatophagoides PteronyssinusDanmark